Who owns Grace Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of GRCE from SEC Form 13F filings across 33 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 33 institutions disclosed 3.8M shares of Grace Therapeutics, Inc. worth $8.7M — about 22.3% of shares outstanding; the largest disclosed holder is Cerity Partners LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
33
13F holders
$8.7M
value, 2026 filers
22.3%
of shares outstanding (3.8M sh)
10
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of GRCE's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Cerity Partners LLC | 849,055 | $1.9M | 0.0% | 4.9% | 0.0% |
| 2 | Eversept Partners, LP | 772,900 | $1.8M | 0.1% | 4.5% | +2.2% |
| 3 | BANK OF AMERICA CORP /DE/ | 494,698 | $1.1M | 0.0% | 2.9% | 0.0% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 411,714 | $934,591 | 0.0% | 2.4% | +2.5% |
| 5 | CITADEL ADVISORS LLC | 349,740 | $793,910 | 0.0% | 2% | +254.2% |
| 6 | Maven Securities LTDNEW | 200,000 | $454,000 | 0.0% | 1.2% | new |
| 7 | Birchview Capital, LP | 120,000 | $272,400 | 0.1% | 0.7% | +140.0% |
| 8 | CANTOR FITZGERALD, L. P.NEW | 100,000 | $227,000 | 0.0% | 0.6% | new |
| 9 | TWO SIGMA INVESTMENTS, LPNEW | 96,890 | $219,940 | 0.0% | 0.6% | new |
| 10 | JANE STREET GROUP, LLC | 89,442 | $203,034 | 0.0% | 0.5% | -46.5% |
| 11 | XTX Topco Ltd | 71,668 | $162,686 | 0.0% | 0.4% | +13.6% |
| 12 | HRT FINANCIAL LPNEW | 62,691 | $142,000 | 0.0% | 0.4% | new |
| 13 | SUSQUEHANNA INTERNATIONAL GROUP, LLPNEW | 49,577 | $112,540 | 0.0% | 0.3% | new |
| 14 | BlackRock, Inc.NEW | 37,535 | $85,205 | 0.0% | 0.2% | new |
| 15 | Rangeley Capital, LLCNEW | 26,000 | $59,020 | 0.1% | 0.2% | new |
| 16 | KESTRA PRIVATE WEALTH SERVICES, LLC | 23,000 | $52,210 | 0.0% | 0.1% | +76.9% |
| 17 | UBS Group AG | 16,777 | $38,084 | 0.0% | 0.1% | -36.2% |
| 18 | Stratos Investment Management, LLCNEW | 11,158 | $25,329 | 0.0% | 0.1% | new |
| 19 | BNP PARIBAS FINANCIAL MARKETS | 10,500 | $23,835 | 0.0% | 0.1% | +47.9% |
| 20 | Scientech Research LLCNEW | 10,184 | $23,118 | 0.0% | 0.1% | new |
| 21 | Virtu Financial LLCNEW | 10,166 | $23,000 | 0.0% | 0.1% | new |
| 22 | OPPENHEIMER & CO INC | 10,000 | $22,700 | 0.0% | 0.1% | 0.0% |
| 23 | MORGAN STANLEY | 9,448 | $21,447 | 0.0% | 0.1% | +107.7% |
| 24 | VANGUARD FIDUCIARY TRUST CO | 8,750 | $19,863 | 0.0% | 0.1% | 0.0% |
| 25 | NATIONAL BANK OF CANADA /FI/ | 2,680 | $6,084 | 0.0% | 0% | -1.3% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.